Advanced Magnetics seeks expanded Feridex use:
This article was originally published in Clinica
Advanced Magnetics has submitted a supplemental new drug application (sNDA) to the US FDA to expand the indications of its Feridex IV MRI contrast agent. The product is currently cleared to aid in the detection of liver lesions, but the Cambridge, Massachusetts company seeks approval to use the agent for characterising the lesions as benign or metastatic. In addition, the company would like a more convenient, rapid infusion, dosing regimen.